ORKA — Oruka Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
$92.11
-$0.51 (-0.55%)
Oruka Therapeutics, Inc. (ORKA) is a biotechnology company listed on NASDAQ. It is led by Lawrence Otto Klein Ph.D., based in 855 Oak Grove Avenue, Menlo Park, CA, United States, 94025, with about 68 employees. Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Net income was -$30.3M. ORKA currently screens at market cap $4.27B.
Use this ORKA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ORKA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ORKA SEC filings page. Lician reads the product cache first so this HTML stays unique to Oruka Therapeutics, Inc. even when a live quote feed is slow.
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
ORKA Key Statistics
Market Cap
$4.27B
Volume
52,023
Previous Close
$91.14
Day Range
$87.57 – $91.08
P/B Ratio
8.84
EPS
-$3.87
Revenue
$0.00
Net Income
-$83.72M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
68
ORKA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$83.72M | -$5.34M | -$9.93M |
| EPS (Diluted) | -$3.87 | -$0.37 | -$0.69 |
Total Assets
$396.02M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$61.58M
Operating Cash Flow
-$57.84M
Free Cash Flow
$0.00
Oruka Therapeutics, Inc. Company Information
- President, CEO & Director
- Lawrence Otto Klein Ph.D.
- Headquarters
- 855 Oak Grove Avenue, Menlo Park, CA, United States, 94025
- Website
- orukatx.com
- Phone
- 650 606 7910
- IPO / Founded
- 1997-08-08
- Sector
- Healthcare
- Industry
- Biotechnology